Key facts
- This page summarizes Miriam Kidron's Form 4 filing for ORAMED PHARMACEUTICALS INC. (ORMP).
- 8 reported transactions and 6 derivative rows are listed below.
- Accepted by SEC: 25 Sep 2026, 16:30.
Miriam Kidron - 24 Sep 2026 Form 4 Insider Report for ORAMED PHARMACEUTICALS INC. (ORMP)
- Reporting relationship
- Chief Scientific Officer, Director
- Issuer ticker
- ORMP
- Reported as of
- 24 Sep 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 25 Sep 2026, 16:30:59 UTC
- Prior SEC filing
- 31 Mar 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Miriam Kidron
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Miriam Kidron filed Form 4 for ORAMED PHARMACEUTICALS INC. (ORMP) on 25 Sep 2026.
Change
- Previous filing in this sequence was filed on 31 Mar 2026.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001409232
Primary reporting owner
Kidron Miriam
- Relationship
- Chief Scientific Officer, Director
- Address
- 1185 AVENUE OF THE AMERICAS, THIRD FLOOR, NEW YORK
- Signature
- /s/ Miriam Kidron
- Signature date
- 25 Sep 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ORMP
transaction
Common Stock
Award
- Transaction value
- Shares
- +208,125
- Change %
- +18%
- Price
- Shares after
- 1,341,263
- Date
- 24 Sep 2026
- Ownership
- Direct
- Footnotes
- F1
ORMP
transaction
Common Stock
Award
- Transaction value
- Shares
- +209,291
- Change %
- +16%
- Price
- Shares after
- 1,550,554
- Date
- 24 Sep 2026
- Ownership
- Direct
- Footnotes
- F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ORMP
transaction
Derivative
Stock option (right to buy)
Disposed to Issuer
- Transaction value
- Shares
- -104,000
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 24 Sep 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 104,000
- Exercise price
- $3.16
- Footnotes
- F1, F3
ORMP
transaction
Derivative
Stock option (right to buy)
Disposed to Issuer
- Transaction value
- Shares
- -100,000
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 24 Sep 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 100,000
- Exercise price
- $4.80
- Footnotes
- F1, F4
ORMP
transaction
Derivative
Stock option (right to buy)
Disposed to Issuer
- Transaction value
- Shares
- -69,999
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 24 Sep 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 69,999
- Exercise price
- $7.77
- Footnotes
- F1, F5
ORMP
transaction
Derivative
Stock option (right to buy)
Disposed to Issuer
- Transaction value
- Shares
- -47,000
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 24 Sep 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 47,000
- Exercise price
- $8.14
- Footnotes
- F1, F6
ORMP
transaction
Derivative
Stock option (right to buy)
Disposed to Issuer
- Transaction value
- Shares
- -100,000
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 24 Sep 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 100,000
- Exercise price
- $10.40
- Footnotes
- F1, F7
ORMP
transaction
Derivative
Stock option (right to buy)
Disposed to Issuer
- Transaction value
- Shares
- -72,000
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 24 Sep 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 72,000
- Exercise price
- $13.89
- Footnotes
- F1, F8
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 8 footnotes
Footnote F1
On September 24, 2026, the issuer canceled all outstanding stock options held by the reporting person pursuant to an option exchange program approved by the Compensation Committee of the issuer's Board of Directors. In exchange for the canceled options, the reporting person received a restricted stock award of an aggregate of 208,125 shares, which fully vested upon grant, valued at $4.75 per share (the closing price on September 22, 2026), equal to the aggregate Black-Scholes value of the canceled options. The option cancellation and restricted stock grant were each approved in advance by a committee of non-employee directors.
Footnote F2
On September 24, 2026, the issuer granted to the reporting person a restricted stock award of an aggregate of 209,291 shares pursuant to the issuer's Amended and Restated 2019 Stock Incentive Plan (the "Plan"). The restricted stock vests as to forty percent (40%) on the date of grant and as to the remaining sixty percent (60%) in eight (8) substantially equal quarterly installments over the twenty-four (24) month period following the date of grant, subject to the reporting person's continued service with the issuer. Unvested shares are subject to forfeiture in accordance with the terms of the applicable award agreement and the Plan.
Footnote F3
The canceled option provided for vesting in 4 equal installments of 26,000 on each of December 31, 2019, December 31, 2020, December 31, 2021 and December 31, 2022.
Footnote F4
The canceled option provided for vesting in 4 equal installments as follows: 25,000 shall vest on each of December 31, 2020, December 31, 2021, December 31, 2022 and December 31, 2023.
Footnote F5
The canceled option provided for vesting in 3 equal installments of 23,333 on each of December 31, 2017, December 31, 2018 and December 31, 2019.
Footnote F6
The canceled option provided for vesting in 4 equal installments of 11,750 on each of January 1, 2019, January 1, 2020, January 1, 2021 and January 1, 2022.
Footnote F7
The canceled option provided for vesting in 4 equal installments as follows: 25,000 shall vest on each of December 31, 2021, December 31, 2022, December 31, 2023 and December 31, 2024.
Footnote F8
The canceled option provided for vesting in 4 equal installments as follows: 18,000 shall vest on each of January 1, 2023, January 1, 2024, January 1, 2025 and January 1, 2026.